Cell Therapies Pty Ltd (CTPL) is a recognised leader in manufacturing and distribution of cell-based therapies. We are the most experienced contract manufacturer in the Asia Pacific region with 15 years of GMP contract manufacturing under Australia’s Therapeutic Goods Administration manufacturing licenses. CTPL provides a “needle-to-needle” service including oversight and management of tissue collection through cell processing and distribution to transplant. We support entire product lifecycles from initial research translation and process optimisation through clinical trial manufacturing and commercial supply. Our experience spans all major cell families including MSC’s and immune cells and key applications from gene and immunotherapies to cell therapies and regenerative medicine. We have a particular interest in understanding and managing the variability of incoming cellular starting materials and provide apheresis site management services to customers globally. Our partnership with Pharmabio of Japan enables us to offer a single gateway to Asia Pacific under a harmonised quality system. Our partnership with Peter MacCallum Cancer Centre (also our majority owner) ensures that we can bring deep research, clinical and process expertise to all clients very efficiently, maximising the advantages of Australia’s favourable and internationally recognised clinical trial approval system and R&D tax incentives. Our brand new production facilities at Peter Mac comprise 10 PIC/S Grade B clean rooms and associated Grade C quality control laboratories. We are proud to be working with some of the world’s leading stem cell companies on some of the most innovative and transformational therapies in medicine today.
Delivering flexible solutions for cellular therapies from the lab bench to the market place in the Pan-Asian region.